Company Overview of Blueprint Medicines Corporation
Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets. The company’s lead drug candidates include BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor, as well as targets the KIT D816V mutation; and BLU-554, an orally available, potent, selective, and irreversible inhibitor, which targets FGFR4. It is also developing a drug candidate to target RET, a receptor tyrosine kina...
215 First Street
Cambridge, MA 02142
Founded in 2008
Key Executives for Blueprint Medicines Corporation
Chief Executive Officer, President and Director
Principal Financial and Accounting Officer and Chief Business Officer
Senior Vice President of Clinical Development
Compensation as of Fiscal Year 2014.
Blueprint Medicines Corporation Key Developments
Blueprint Medicines Corporation(NasdaqGS:BPMC) added to NASDAQ Composite Index
May 1 15
Blueprint Medicines Corporation has been added to Nasdaq Composite Index.
Blueprint Medicines Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity of BLU-285 in Treatment-Resistant Gist and on Novel Cancer Drug Targets
Apr 19 15
Blueprint Medicines announced new preclinical data demonstrating that its drug candidate BLU-285 has significant anti-tumor activity in treatment-resistant models of gastrointestinal stromal tumors (GIST) and achieved and maintained complete tumor regression in all mice treated at the high dose level. These data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2015. Blueprint Medicines also presented data identifying new cancer drug targets during a minisymposium at AACR on cancer genomics. Using proprietary computational tools to identify kinase fusions involved in cancer, the Company uncovered 16 known fusions in new cancer types and identified 21 novel fusions across six genes that likely play a key role in cancer. In addition to paving the way for the discovery and development of novel therapies, these findings could have immediate implications for the diagnosis and treatment of cancer patients. BLU-285 is a highly targeted drug that potently and selectively inhibits PDGFRa D842V and KIT Exon 17 mutants, which are receptor tyrosine kinase mutants known to be key drivers in treatment-resistant and metastatic GIST. Because BLU-285 binds to regions of the PDGFRa and KIT kinases that are structurally similar, it is able to simultaneously inhibit PDGFRa D842V and KIT Exon 17 mutants with minimal inhibition of other kinases, potentially limiting the off-target side effects associated with many cancer treatments. The new preclinical data presented at AACR show that BLU-285 induces significant tumor regression in a patient-derived in vivo model of GIST that is refractory to treatment with imatinib, an approved first-line treatment for GIST. Key findings include: BLU-285 achieved and maintained complete tumor remission in 100% of mice treated with an oral, once daily dose of 30 mg/kg or 100 mg/kg for 28 days; Complete tumor regression was maintained during a 28-day observation period following treatment at the 100 mg/kg dose. Blueprint Medicines is on track to file an Investigational New Drug (IND) Application and begin a Phase 1 clinical trial of BLU-285 in mid-2015 that will include GIST patients whose cancer is driven by PDGFRa D842V and KIT Exon 17 mutants. The Company also plans to file an IND and begin a Phase 1 clinical trial in mid-2015 for BLU-285 in patients with systemic mastocytosis, another disease with significant unmet need in which a KIT Exon 17 mutant plays a key role.
Blueprint Medicines Appoints Charles A. Rowland, Jr. to its Board of Directors
Mar 23 15
Blueprint Medicines announced the appointment of Charles A. Rowland Jr., CPA, to its Board of Directors. Mr. Rowland brings more than 30 years of experience in biopharmaceutical financial management and strategic business operations. Mr. Rowland most recently served as the Vice President and Chief Financial Officer (CFO) of ViroPharma. In this role, he oversaw all aspects of finance, including financial analysis and reporting, tax, treasury and investor relations, as well as strategic business planning and information technology.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 10, 2014